{
    "title": "Hair Follicle Regeneration",
    "inventor_name": "George COTSARELIS et al",
    "publication_year": 2013,
    "device_name": "Follica minimally invasive skin perturbation device",
    "goal": "Regenerate new hair follicles to treat baldness and other hair-loss conditions",
    "problem_addressed": "Androgenetic alopecia (male-pattern baldness) and other follicle-degeneration disorders",
    "concept_summary": "The technology uses a minimally invasive skin-perturbation device to remove the superficial epidermal layers, triggering dedifferentiation of skin cells into a stem-like state. A topical formulation containing molecular agents (e.g., EGFR inhibitors, FGF9, Wnt proteins, retinoids, anti-androgens) is then applied to direct these cells to form de-novo hair follicles. Pre-clinical mouse studies and early human trials report consistent follicle neogenesis and significant increases in follicle numbers when key pathways such as Wnt or FGF9 are modulated.",
    "detailed_description": null,
    "category": "Medical & Dental Technologies",
    "principles": [
        "Wound-healing induced epidermal dedifferentiation",
        "Modulation of Wnt signaling",
        "Application of fibroblast growth factor-9 (Fgf9)",
        "EGFR pathway inhibition",
        "Topical delivery of growth-factor cocktails"
    ],
    "scientific_domains": [
        "Dermatology",
        "Regenerative Medicine",
        "Molecular Biology",
        "Cell Biology"
    ],
    "mechanisms_of_action": [
        "Mechanical disruption of epidermis creates a transient stem-cell-like state",
        "Topical agents activate signaling pathways (Wnt, Fgf9, EGFR) that drive follicle lineage commitment",
        "Inhibition of EGFR promotes differentiation toward hair-follicle fate"
    ],
    "materials": [
        "Small-molecule EGFR inhibitors (e.g., leflunomide, gefitinib, erlotinib, lapatinib)",
        "EGFR antibodies (e.g., cetuximab, zalutumumab)",
        "Recombinant FGF9 polypeptide",
        "Wnt ligands or agonists",
        "Retinoids (e.g., 13-cis-retinoic acid, all-trans-retinoic acid)",
        "Anti-androgens (e.g., finasteride, dutasteride, RU58841)",
        "Minoxidil (channel opener)",
        "Anti-inflammatory corticosteroids",
        "Antihistamines (e.g., diphenhydramine)"
    ],
    "energy_sources": [],
    "inputs": [
        "Patient skin (epidermis)",
        "Topical composition containing the above molecular agents"
    ],
    "outputs": [
        "De-novo hair follicles",
        "Visible hair growth"
    ],
    "claimed_performance": "Pre-clinical mouse studies show up to a 23-fold increase in follicle formation with Fgf9 over-expression; early human trials report consistent creation of new follicles after device treatment and topical application.",
    "experimental_evidence": "Nature 2007 (Wnt modulation) and Nature Medicine 2013 (Fgf9) studies in mice; Follica's own pre-clinical and early-phase clinical trials (as reported in The Scientist article).",
    "replication_status": "Pre-clinical mouse data published; early human trial data reported by Follica; no independent third-party replication documented.",
    "keywords": [
        "Hair follicle neogenesis",
        "Wound healing",
        "Wnt signaling",
        "Fgf9",
        "EGFR inhibition",
        "Dermatology",
        "Regenerative medicine"
    ],
    "related_technologies": [
        "Minoxidil therapy",
        "Finasteride therapy",
        "Hair transplantation",
        "Microneedling",
        "Stem-cell based skin regeneration"
    ],
    "controversy_level": "low",
    "confidence_score": 0.9,
    "practicability_score": 0.7,
    "fringe_score": 0.2,
    "evidence_strength": 0.7,
    "risk_score": 0.2,
    "trl_estimate": 6,
    "source_urls": [
        "http://www.the-scientist.com/?articles.view/articleNo/37149/title/A-Hair-Raising-Solution-/",
        "http://www.nature.com/nature/journal/v447/n7142/abs/nature05766.html",
        "https://patents.google.com/patent/US2012156228",
        "https://patents.google.com/patent/US2012121693",
        "https://patents.google.com/patent/WO2010056759"
    ],
    "organizations": [
        "Follica",
        "PureTech Ventures",
        "University of Pennsylvania Perelman School of Medicine",
        "Kligman Laboratories"
    ],
    "applications": [
        "Treatment of androgenetic alopecia",
        "Regeneration of hair follicles after scarring",
        "General skin regeneration therapies"
    ],
    "limitations": [
        "Requires controlled epidermal disruption (potential for scarring)",
        "Long-term safety of repeated skin perturbation not yet known",
        "Regulatory approval pending for many of the topical agents"
    ],
    "open_questions": [
        "What is the durability of newly formed follicles over years?",
        "Can the method be scaled to large scalp areas without adverse effects?",
        "What are the optimal dosing regimens for each molecular component?"
    ],
    "red_flags": [],
    "evidence_quotes": [
        "\"Inhibition of Wnt signalling after re-epithelialisation completely abrogates this wounding-induced folliculogenesis, whereas over-expression of Wnt ligand in the epidermis increases the number of regenerated hair follicles.\" - Nature 2007",
        "\"When the researchers induced over-expression of Fgf9, new follicle formation increased 23-fold compared with normal expression.\" - Nature Medicine 2013",
        "\"Follica has already done pre-clinical and clinical trials, all of which confirm that we can consistently create new hair follicles in mice and in humans.\" - The Scientist article, 2013"
    ]
}